Introduction and objective:
Vaccinations as one of the highest achievements of medicine contributed to a significant reduction of infectious diseases. According to the current vaccination calendar in Poland, parent have possibility to choose free cost classic (DTP, polio, HBV) and not refundable 5- or 6-component combination vaccine. The aim of the study was to assess the popularity of the 5- and 6-component combination vaccines in years 2010-2019 among infants' parents starting a mandatory vaccination series in a selected Primary Health Care Clinic.

Material and methods:
The study was conducted at Med-All Medical Centre in Krakow which provided Protective Vaccination Program and included 1108 immunization cards of children born between 2010-2019. Most of the sample (98.5%) lived in Cracow. This retrospective ecological study was used analysis of medical records. Data analysis MS Excel (Microsoft) and PQStat Soft. The significance level was p< 0.05.

From 2010 to 2016, 5-component combination vaccine was the most popular choice for infants. During the study period the 5-component combination vaccine usage decrease with years (p=0.017). From 2017, the most popular was the 6-component vaccine and the usage increase with years with strong statistically significance (p=0.005). In 2019 there was the largest percentage of unvaccinated infants.

Despite the costs, in 2010-2016, the most popular vaccine for infants was the 5-component high-combination vaccine. Since 2017, the 6-component vaccine has gained the greatest popularity.

Gołąb J, Jakóbisiak M, Lasek W, et al. Immunologia. Warszawa: Wydawnictwo naukowe PWN; 2017. p. 312–326.
Male D, Brostoff J, Roth D B, et al. Immunologia. Warszawa: Elsevier Urban & Partner; 2008. p. 325–339.
European Medicines Agency gives first opinion for a vaccine for use outside the EU. European Medicines Agency (EMA). [accessed 29.04.2021].
Hexacima EPAR. European Medicines Agency (EMA). [accessed 29.04.2021].
Hexyon EPAR. European Medicines Agency (EMA). [accessed 29.04.2021].
Vaxelis EPAR. European Medicines Agency (EMA). [accessed 29.04.2021].
Program Szczepień Ochronnych w 2020 roku. [accessed 10.02.2020].
Wysocki J, Czajka H. Szczepienia w pytaniach i odpowiedziach. Kraków: Help-Med; 2018. p. 133–150.
Dolhain J, Janssens W, Sohn W-Y, et al. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region. Expert Rev Vaccines 2019; 18: 921–933.
Kramarz P, Pędziński B, Giesecke J. Tiomersal jako składnik szczepionek. Aktualny stan wiedzy. Med Prakt Pediatr. 2010; 1: 5–12, 7.
Zawadka M, Lutyńska A. Immunogenność i odczynowość bez komórkowych szczepionek przeciw krztuścowi przeznaczonych dla młodzieży i osób dorosłych. Przegl Epidemiol. 2012; 66: 99–105.
Szymoniak K, Cholewa D, Fryc D, et al. Opinia rodziców na temat odmowy wykonania szczepień ochronnych u dzieci. Piel Pol. 2020; 77 (3): 159–165.
Koperny M, Kargul A, Seweryn M, et al. The prevalence of combination vaccines for children in Europe. Analysis of the availability and funding. JHPOR 2014; 2: 18–31.
Monge S, Hahné S J, de Melker H E, et al. Effectiveness of the DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003–16): a casecontrol study. The Lancet Inf Dis. 2018; 18: 749–757.
Pieszka M, Waksmańska W, Woś H. Wiedza rodziców dzieci do drugiego roku życia na temat szczepień ochronnych. Med Og Nauk Zdr. 2016; 22: 221–226.
Nitsch-Osuch A, Kozerska A, Topczewska-Cabanek A, et al. Realization of immunization schedule with recommended vaccines among children from one general practice. Fam Med Prim Care Rev. 2012; 14: 410–413.
Pomian- Osiak A, Owłasiuk A, Gryko A, et al. Vaccination of children at the age of 0–2 with combination and recommended vaccines – assessment of the frequency of use and the knowledge of parents. Probl Med Rodz. 2014; 3: 18–27.
Kędzierska A K. Realizacja szczepień ochronnych u dzieci do drugiego roku życia. Pielęg Pol. 2019; 73: 252–257.
Hubicki L, Czech E, Kowalska M, et al. Szczepienia ochronne dzieci w rodzinach o różnym stanie społecznoekonomicznym w Bytomiu. Przegl Epidemiol. 2004; 58: 713–723.
Gańczak M, Dmytrzyk-Daniłów G, Karakiewicz B, et al. Determinants influencing selfpaid vaccination coverage, in 0–5 years old Polish children. Vaccine. 2013; 31: 5687–5692.
Obando-Pacheco P, Rivero-Calle I, Raguindin PF, et al. DTaP5-HBV-IPV-Hib paediatric hexavalent combination vaccine for use in children from 6 weeks through to 4 years of age. Expert Rev Vaccines. 2019; 18: 1115–1126.